This review discusses the evidence in support of the use of riluzole, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Matthew Kiernan, Professor of Neurology and Staff Specialist at the Royal Prince Alfred Hospital and the Bushell Chair of Neurology at the University of Sydney.
Please login below to download this issue (PDF)